1. Home
  2. Companies
  3. RGT
  4. Material Events

Argent Biopharma (ASX:RGT) — Material Events

ASX:RGT · 13 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Argent BioPharma Posts A$17.8M Loss Amid Strategic Shift and EU ExpansionMedium
Argent BioPharma posts A$17.8M loss, advances clinical pipeline, secures EU approvals, and raises capital
29 Aug 2025 ·Annual Report ·85
Argent BioPharma’s AusCann Acquisition Sets Stage for U.S. Market LeapHigh
Argent BioPharma Acquires AusCann Assets, Advances Clinical Programs, and Reports Q3 2025 Cash Flow
31 Oct 2025 ·Quarterly Activity Report and Appendix 4C Cash Flow Statement ·85
Argent BioPharma Secures A$11m to Complete AusCann Deal and Eye US ListingHigh
Argent BioPharma secures A$11m funding to complete AusCann acquisition and pursue US listing
17 Nov 2025 ·Capital Raising ·85
Argent BioPharma Streamlines CannPal Acquisition to Boost CannEpil PipelineMedium
Argent BioPharma to acquire CannPal stake from AusCann, enhancing CannEpil pipeline and IP
14 Jan 2026 ·Asset Acquisition ·85
Independent US Study Validates ArtemiC™’s Breakthrough in Viral InflammationMedium
Independent US Study Shows ArtemiC™ Significantly Improves Survival in Severe Viral Inflammation Model
25 Aug 2025 ·Clinical Study Results ·85
Argent BioPharma Licenses CannEpil® Globally to Splash Beverage for US$5.5M Upfront and 15% RoyaltiesMedium
Argent BioPharma licenses CannEpil® globally to Splash Beverage for US$5.5M upfront and 15% royalties
7 July 2026 ·Licensing Agreement ·85
Argent BioPharma Acquires AusCann Assets, Boosting EU Reach and PipelineHigh
Argent BioPharma to acquire AusCann assets, boosting clinical pipeline and EU presence ahead of US listing
19 Aug 2025 ·Acquisition Announcement ·85
Argent BioPharma Advances EU Epilepsy Treatment Supply and Secures German ApprovalMedium
Argent BioPharma advances EU epilepsy treatment supply, gains German approval, and secures manufacturing deals
31 July 2025 ·Quarterly Activity Report and Appendix 4C ·80
Argent BioPharma Completes CannPal Acquisition, Adds Neuvis® Option to Boost Epilepsy PipelineMedium
Argent BioPharma completes CannPal acquisition and secures Neuvis® option, boosting epilepsy portfolio
13 Apr 2026 ·Acquisition Completion ·80
Argent BioPharma Narrows Loss, Advances CannEpil Acquisition, Secures A$11M FundingMedium
Argent BioPharma narrows half-year loss, advances CannEpil acquisition, secures A$11M funding
27 Feb 2026 ·Interim Financial Report ·80
Argent BioPharma Reshapes AusCann Deal, Secures A$11M Funding BoostMedium
Argent BioPharma restructures AusCann asset acquisition, secures A$11M funding, reports December quarter cash flow
30 Jan 2026 ·Quarterly Activity Report and Appendix 4C Cash Flow Statement ·80
Argent BioPharma Expands Portfolio with CannPal Acquisition and Boosts EU SalesMedium
Argent BioPharma expands portfolio with CannPal acquisition, ships largest CannEpil order to Ireland, and files US patent for NanoBodies platform
29 Apr 2026 ·Quarterly Activity Report and Appendix 4C ·80
Argent BioPharma Delivers Largest CannEpil® Shipment to Ireland, Valued at AUD 783KMedium
Argent BioPharma Ships Largest CannEpil® Batch to Ireland, Valued at AUD 783K
23 Feb 2026 ·Commercial Shipment Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.